While federal attention to digital therapeutics reimbursement has focused on Medicare fee schedule codes, a quieter and arguably more consequential experiment is happening at the state level. Several state Medicaid agencies have begun building their own coverage frameworks for app based behavioral health interventions, moving independently of any single federal template and producing a patchwork that looks different from state to state.
Medicaid is a useful place to watch this play out because the population it serves has a disproportionately high burden of behavioral health need alongside some of the weakest access to in person specialty care, particularly in rural counties where psychiatrists and licensed therapists are scarce. A digital therapeutic that a patient can use on a phone without traveling to an appointment is, in principle, well suited to exactly the access gap Medicaid programmes struggle most to close. Whether that principle translates into workable coverage policy is the open question several states are now testing.
Different states, different mechanisms
Some states have moved through their Medicaid preferred drug list and durable medical equipment adjacent processes, treating an FDA authorized digital therapeutic similarly to how they would treat a prescribed medical device, with a defined billing code and a per patient authorization process. Others have taken a managed care organization route, allowing the private insurers that administer Medicaid benefits in that state to negotiate coverage directly with digital therapeutic vendors, which produces faster movement in some plans but a less consistent statewide standard. A smaller number of states have launched formal pilot programmes, often tied to specific conditions such as substance use disorder or pediatric behavioral health, with built in evaluation periods before any decision on permanent coverage.
This variation is not simply bureaucratic inconsistency. Medicaid programmes are run by individual states with different budgets, different behavioral health workforce shortages, and different political appetite for new spending categories, so a coverage model that works administratively in one state may not transfer cleanly to another. For companies selling into this market, it means a state by state go to market strategy is currently unavoidable, in sharp contrast to the single national negotiation a Medicare code change represents.
Why this matters beyond Medicaid itself
Medicaid coverage decisions have historically had influence beyond the programme itself. When a state Medicaid agency establishes a billing code and a clinical justification for covering a category of treatment, that documentation often becomes a reference point commercial payers and other state programmes draw on, even though they are not bound by it. Digital therapeutics vendors are aware of this dynamic and have in some cases prioritized building relationships with a handful of Medicaid agencies specifically because early state coverage decisions can accelerate broader market acceptance in ways that are hard to achieve through commercial payer negotiations alone.
There is also a practical access argument that resonates differently in Medicaid than in commercial insurance. A meaningful share of Medicaid enrollees live in behavioral health workforce shortage areas, and state officials evaluating digital therapeutics are often doing so against the alternative of no treatment at all, rather than against a robust in person option. That framing has made some state officials more willing to experiment with app based interventions than commercial payers serving populations with more provider choice.
The risks in moving early
States moving first are also taking on more risk. Evaluating whether a digital therapeutic is producing real clinical benefit in a Medicaid population, which often has more complex comorbidities and greater social barriers to consistent app engagement than the population studied in a company's pivotal trial, requires evaluation infrastructure many state Medicaid agencies do not have in house. Some of the more cautious states are explicitly building evaluation partnerships with academic institutions before committing to permanent coverage, which is a more rigorous but slower path than simply adding a billing code and moving on.
Key Signals
State Medicaid agencies are building independent coverage pathways for digital therapeutics through preferred drug list mechanisms, managed care negotiation, and formal pilot programmes, producing meaningful variation across states rather than a single national standard. This state level activity is filling a gap left by narrow federal reimbursement rules and may prove more influential on long run market access than any single Medicare fee schedule change. Digital therapeutics vendors are treating early state Medicaid relationships strategically, aware that documented coverage decisions can shape how commercial payers and other states evaluate the same products. The central risk is that few state Medicaid agencies have the evaluation infrastructure to rigorously assess real world outcomes in their own populations, meaning early coverage decisions may rest on thinner evidence than the pivotal trials that supported FDA authorization.
